research use only

Tazemetostat hydrobromide EZH2 inhibitor

Cat.No.E4850

Tazemetostat hydrobromide (EPZ-6438 hydrobromide) is a potent, selective, and orally available inhibitor of EZH2. It inhibits EZH2 with IC50 values of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat hydrobromide also inhibits EZH1 with an IC50 of 392 nM.
Jump to

Quality Control

Batch: Purity: 99.50%
99.50

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (152.98 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 3 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 653.65 Formula

C34H44N4O4.BrH

Storage (From the date of receipt)
CAS No. 1467052-75-0 Download SDF Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC50/Ki
EZH2
11 nM
EZH2
16 nM
EZH1
392 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-04-02)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05994235 ACTIVE_NOT_RECRUITING
Follicular Lymphoma
Weill Medical College of Cornell University
2023-11-01 PHASE2
NCT06824701 ACTIVE_NOT_RECRUITING
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah
2025-09-12 PHASE1
NCT06068881 WITHDRAWN
Follicular Lymphoma; Refractory Follicular Lymphoma
Epizyme, Inc.
2025-09-02 PHASE2
NCT06575686 SUSPENDED
Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma
City of Hope Medical Center
2025-03-11 PHASE2
NCT05627232 RECRUITING
Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
Thomas Jefferson University
2023-08-28 PHASE1
NCT07407283 RECRUITING
Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
2026-04-08 PHASE1; PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.